%0 Generic %A R., Niikura %A A., Yamada %A M., Fujishiro %A K., Tanaka %A K., Matsuda %A Y., Saito %A K., Ohtsuka %A I., Oda %A C., Katada %A M., Kato %A M., Kida %A K., Kobayashi %A S., Hoteya %A T., Horimatsu %A S., Kodashima %A T., Matsuda %A M., Muto %A H., Yamamoto %A S., Ryozawa %A R., Iwakiri %A H., Kutsumi %A H., Miyata %A K., Haruma %A K., Fujimoto %A N., Uemura %A M., Kaminishi %A T., Shinozaki %A H., Tajiri %A K., Koike %D 2018 %T Supplementary Material for: The Effects of Direct Oral Anticoagulants, Warfarin, Aspirin and Thienopyridine on the Performance of Immunochemical, Faecal, Occult Blood Tests %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_The_Effects_of_Direct_Oral_Anticoagulants_Warfarin_Aspirin_and_Thienopyridine_on_the_Performance_of_Immunochemical_Faecal_Occult_Blood_Tests/7315079 %R 10.6084/m9.figshare.7315079.v1 %2 https://karger.figshare.com/ndownloader/files/13514636 %K Colorectal neoplasia %K Direct oral anticoagulant %K Immunochemical faecal occult blood test %X Aim: To clarify whether antithrombotic drugs affect diagnosis using the immunochemical faecal occult blood test ­(iFOBT) of colorectal neoplasia. Methods: Using the Japan Endoscopy Database from 8 centres between 2015 and 2017, we analyzed data about patients who were iFOBT positive and had received direct oral anticoagulants (DOAC), warfarin, aspirin or thienopyridine. One-to-one matching-analogue propensity score weighted analyses were performed to compare the positive predictive value (PPV) of all neoplasms, invasive and non-invasive colorectal cancers and adenomas between drug users and non-users. All neoplasms included invasive and non-invasive colorectal cancer, and adenomas. Results: We analyzed 197 DOAC users and 196 non-users, 153 warfarin users and 153 non-users, 408 aspirin users and 415 non-users, and 97 thienopyridine users and 97 non-users. No significant differences were observed in the PPV for all neoplasms (56.67 vs. 50.43%), invasive cancer (4.32 vs. 3.53%), non-invasive cancer (15.58 vs. 15.56%) or adenoma (53.13 vs. 48.09%) between the DOAC user and non-user groups. No significant differences were observed in the PPV for all neoplasia, invasive and non-invasive cancer, or adenoma between warfarin, aspirin and thienopyridine use and non-users. Conclusions: DOAC, warfarin, aspirin and thienopyridine use did not decrease the PPVs of the iFOBT used to evaluate all colorectal neoplasia. %I Karger Publishers